Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug;41(4):457-460.
doi: 10.1007/s10585-023-10228-4. Epub 2023 Aug 9.

Oncolytic intralesional therapy for metastatic melanoma

Danielle K DePalo #  1 , Matthew C Perez #  1 , Anne Huibers  2   3 , Roger Olofsson Bagge  2   3 , Jonathan S Zager  4   5
Affiliations
Review

Oncolytic intralesional therapy for metastatic melanoma

Danielle K DePalo et al. Clin Exp Metastasis. 2024 Aug.

Abstract

In-transit metastasis (ITM) develop in approximately 1 in 10 patients with melanoma and the disease course can vary widely. Surgical resection is the gold-standard treatment; however, ITM are often surgically unresectable due to size, distribution, and/or anatomic involvement. Oncolytic viral therapies are one category of non-surgical treatment options available for ITM. They induce tumor cell lysis and systemic anti-tumor activity through selective infection of tumor cells by naturally occurring or genetically modified factors. While there are numerous oncolytic viral therapies in various stages of development for the treatment of ITM, this discussion focuses on the mechanism and available literature for the two most established herpes virus-based therapies.

Keywords: Intralesional oncolytic viral therapy intranist disease; Melanoma; Metastatic melanoma; Regional chemotherapy; Regionally metastatic melanoma.

PubMed Disclaimer

References

    1. Borgstein PJ, Meijer S, van Diest PJ (1999) Are locoregional cutaneous metastases in melanoma predictable? Ann Surg Oncol 6(3):315–321 - DOI - PubMed
    1. Pawlik TM, Ross MI, Thompson JF, Eggermont AM, Gershenwald JE (2005) The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol 23(21):4588–4590 - DOI - PubMed
    1. Gershenwald JE, Scolyer RA, Hess KR et al (2017) Melanoma staging: evidence-based changes in the american Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(6):472–492 - DOI - PubMed - PMC
    1. Wesslau H, Carlander A, Ny L, Wärnberg F, Olofsson Bagge R, Lindqvist Bagge AS (2022) Tumor Burden and Health-Related Quality of Life in patients with Melanoma In-Transit metastases. Cancers (Basel). 15(1)
    1. Morton DL, Eilber FR, Holmes EC et al (1974) BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 180(4):635 - DOI - PubMed - PMC

LinkOut - more resources